Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells

The proteasome plays a pivotal role in the turnover of regulatory transduction proteins induced by activated cell membrane growth factor receptors. The epidermal growth factor receptor (EGFR) pathway is crucial in the development and progression of human epithelial cancers. Proteasome inhibition may sensitize human cancer cell lines to EGFR inhibitors. We investigated the growth inhibitory and pro‐apoptotic effects of the proteasome inhibitor bortezomib in combination with anti‐EGFR drugs, such as gefitinib, vandetanib, and cetuximab in EGFR‐expressing human cancer cell lines. Bortezomib determined dose‐dependent growth inhibition in a nine cancer cell line panel (IC50 values, range 6–42 nM). A significant synergistic growth inhibitory effect was observed with the combination of bortezomib and each EGFR inhibitor in all cell lines (combination index, CI, range 0.10–0.55), which was accompanied by a significant induction in apoptosis by the combined treatment with bortezomib, cetuximab and vandetanib. In HCT‐116 colon cancer and A549 lung adenocarcinoma cells, bortezomib plus EGFR inhibitor treatment induced a more effective inhibition of EGFR‐activated down‐stream signals, including a marked suppression in activated, phosphorylated Akt (P‐Akt). In contrast, overexpression of a constitutively active P‐Akt protected A549 cells by cell growth inhibition and apoptosis following treatment with bortezomib and EGFR inhibitors. The combined treatment with bortezomib and EGFR inhibitors has a synergistic growth inhibitory and pro‐apoptotic activity in different human cancer cells which possess a functional EGFR‐dependent autocrine growth pathway through to a more efficient and sustained inhibition of Akt. J. Cell. Physiol. 216: 698–707, 2008, © 2008 Wiley‐Liss, Inc.

[1]  J. Lorch,et al.  Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. , 2007, Cancer research.

[2]  M. Rettig,et al.  Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib , 2007, Molecular Cancer Therapeutics.

[3]  R. Lotan,et al.  Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. , 2006, Cancer research.

[4]  G. Fontanini,et al.  Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases , 2006, Journal of cellular physiology.

[5]  F. Ciardiello,et al.  Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases , 2006, Molecular Cancer Therapeutics.

[6]  T. Fujita,et al.  Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells , 2006, Anti-cancer drugs.

[7]  B. Mellado,et al.  Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[8]  G. Tortora,et al.  Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Li Han,et al.  Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens* , 2005, Journal of Biological Chemistry.

[10]  G. Fontanini,et al.  Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Baselga,et al.  Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.

[13]  Prakash Chinnaiyan,et al.  Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR) , 2004, Cancer Research.

[14]  R. Pazdur,et al.  Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma , 2004, Clinical Cancer Research.

[15]  C. Sotiriou,et al.  Targeting the ubiquitin-proteasome pathway in breast cancer. , 2004, Clinical breast cancer.

[16]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[17]  G. Mills,et al.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.

[18]  H. Lenz.  Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.

[19]  G. Fontanini,et al.  Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  N. Normanno,et al.  Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. , 2003, Endocrine-related cancer.

[21]  R. Lotan,et al.  Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. , 2003, Journal of the National Cancer Institute.

[22]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[23]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[24]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[25]  E. Dees,et al.  The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer , 2002, Breast Cancer Research.

[26]  J. Minna,et al.  Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. , 2002, Cancer research.

[27]  G. Fontanini,et al.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[29]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[30]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[31]  Joseph Schlessinger,et al.  A Novel Positive Feedback Loop Mediated by the Docking Protein Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling , 2000, Molecular and Cellular Biology.

[32]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[33]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[34]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[35]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[36]  M. Kraus,et al.  Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members , 1994, Molecular and cellular biology.

[37]  T. Chou,et al.  A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. , 1977, The Journal of biological chemistry.

[38]  Huang-Ge Zhang,et al.  EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells. , 2007, Journal of the American Society of Nephrology : JASN.

[39]  D. Ribatti,et al.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.

[40]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[41]  G. Fontanini,et al.  Antitumor Effects of ZD 6474 , a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor , with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase 1 , 2003 .